Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
Clinical Study to Assess the Safety fo AVI-4658 in Subjects With Duchenne Muscular Dystrophy Due to a Frame-shift Mutation Amenable to Correction by Skipping Exon 51.
Sponsor: British Medical Research Council
A PHASE1/PHASE2 clinical study on Duchenne Muscular Dystrophy, this trial is completed. The trial is conducted by British Medical Research Council and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Jan 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- British Medical Research Council
- Sarepta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • London, United Kingdom
- • Newcastle upon Tyne, United Kingdom